Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vistagen Therapeutics Inc    VTGN

VISTAGEN THERAPEUTICS INC

(VTGN)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Regulation FD Disclosure

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:40pm EDT

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

On January 7, 2019, VistaGen Therapeutics, Inc. (the“Company”) began utilizing a new corporate presentation. A copy of the Corporate Presentation is attached hereto as Exhibit99.1.

The information in this Item 7.01 of this Current Report onForm8-K,including the information set forth in Exhibit99.1, is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

In addition, this Current Report on Form 8-K and the exhibit(s) attached hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company’s plans, objectives, expectations and intentions; and (ii) other statements identified by words such as “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties.

Item 9.01 Exhibits.

See Exhibit Index.

VistaGen Therapeutics, Inc. Exhibit

To view the full exhibit click here

About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.

The post VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Regulation FD Disclosure appeared first on Market Exclusive.

© Market Exclusive 2019, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VISTAGEN THERAPEUTICS INC
05/31VISTAGEN THERAPEUTICS : Announces Positive Preclinical Data Supporting AV-101's ..
AQ
05/08VISTAGEN THERAPEUTICS : to Present at ChinaBio Partnering Forum in Shanghai, Chi..
AQ
05/02VISTAGEN THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial ..
AQ
04/04VISTAGEN THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
04/02VISTAGEN THERAPEUTICS : Positive Pilot Phase 3 Data Position VistaGen's PH94B Ne..
AQ
03/14VISTAGEN THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events (form 8-K)
AQ
03/04VISTAGEN THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financ..
AQ
02/26VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Co..
GL
02/26VISTAGEN THERAPEUTICS : Announces Proposed Public Offering of Common Stock
AQ
02/25VISTAGEN THERAPEUTICS : Announces Proposed Public Offering of Common Stock
AQ
More news
Financials ($)
Sales 2020 -
EBIT 2020 -
Net income 2020 -
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -
P/E ratio 2021 -
Capi. / Sales 2020 0
Capi. / Sales 2021 -
Capitalization 32,6 M
Chart VISTAGEN THERAPEUTICS INC
Duration : Period :
Vistagen Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VISTAGEN THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 6,00 $
Spread / Average Target 658%
EPS Revisions
Managers
NameTitle
Shawn K. Singh Chief Executive Officer & Director
H. Ralph Snodgrass President, Director & Chief Scientific Officer
Jon Sheldon Saxe Chairman
Jerrold D. Dotson Chief Financial Officer, Secretary & VP
Mark A. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VISTAGEN THERAPEUTICS INC-49.37%33
CSL LIMITED16.22%64 329
BIOGEN-22.98%43 310
ALEXION PHARMACEUTICALS23.40%25 574
SAMSUNG BIOLOGICS CO LTD--.--%16 821
GRIFOLS8.52%16 048